Education
About Us
Working with TipRanks
Follow Us
Pulmonx Corporation (LUNG)
:LUNG
LUNG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.46 - $10.01
Previous CloseN/A
Volume95.69K
Average Volume (3M)370.63K
Market Cap
$343.05M
Enterprise Value$273.37M
Total Cash (Recent Filing)-$4.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.49
Next Earnings
May 06, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding39,796,420
10 Day Avg. Volume713,039
30 Day Avg. Volume370,635
Standard Deviation0.17
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.09
Price to Cash Flow (P/CF)-12.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.39
Enterprise Value/Ebitda-5.35
Forecast
1Y Price Target
$12.40Price Target Upside43.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Pulmonx News
PremiumCompany Announcements
Pulmonx Corporation’s Earnings Call Reveals Strong Growth and Challenges
PremiumCompany Announcements
Pulmonx Corporation Achieves Record Revenue Growth in 2024---
Bulls Say, Bears Say
Bulls Say
Financial PerformancePulmonx reported a solid Q4 performance with revenue beating both company and consensus estimates, demonstrating strong expense management and better-than-expected profitability.
Growth StrategyManagement issued FY25 guidance that is ahead of company estimates, indicating confidence in continued growth driven by strategic initiatives.
Bears Say
Management ChallengesDespite management turnover and broader MedTech weakness, the current team has been executing effectively to numbers.
---
Ownership Overview
10.78% Insiders
35.93% Mutual Funds
32.41% Other Institutional Investors
5.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LUNG FAQ
What was Pulmonx Corporation’s price range in the past 12 months?
Pulmonx Corporation lowest stock price was $5.46 and its highest was $10.01 in the past 12 months.
What is Pulmonx Corporation’s market cap?
Pulmonx Corporation’s market cap is $343.05M.
When is Pulmonx Corporation’s upcoming earnings report date?
Pulmonx Corporation’s upcoming earnings report date is May 06, 2025 which is in 64 days.
How were Pulmonx Corporation’s earnings last quarter?
Pulmonx Corporation released its earnings results on Feb 19, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.447 by $0.117.
Is Pulmonx Corporation overvalued?
According to Wall Street analysts Pulmonx Corporation’s price is currently Undervalued.
Does Pulmonx Corporation pay dividends?
Pulmonx Corporation does not currently pay dividends.
What is Pulmonx Corporation’s EPS estimate?
Pulmonx Corporation’s EPS estimate is -0.39.
How many shares outstanding does Pulmonx Corporation have?
Pulmonx Corporation has 39,796,420 shares outstanding.
What happened to Pulmonx Corporation’s price movement after its last earnings report?
Pulmonx Corporation reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.447. Following the earnings report the stock price went up 32.229%.
Which hedge fund is a major shareholder of Pulmonx Corporation?
Currently, no hedge funds are holding shares in LUNG
---
Pulmonx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.40 (43.85% Upside)
$12.40 (43.85% Upside)
Blogger Sentiment
Bullish
LUNG Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $61.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.90%
12-Months-Change
Fundamentals
Return on Equity
-55.25%
Trailing 12-Months
Asset Growth
-6.28%
Trailing 12-Months
Company Description
Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
---
LUNG Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Pulmonx demonstrated strong revenue growth and international expansion, with significant advancements in clinical trials and product innovation. However, increased operating expenses and persistent net losses highlight ongoing financial challenges. The future outlook includes strategic initiatives to sustain growth, but foreign exchange fluctuations pose a potential risk.Read More>---
LUNG Stock 12 Month Forecast
Average Price Target
$12.40
▲(43.85% Upside)
Technical Analysis
Insulet
―
NovoCure
―
Irhythm Technologies
―
Inspire Medical Systems
―
TransMedics Group
―
Best Analysts Covering LUNG
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
-12.44%
reiterated a buy rating 12 days ago
Copying Rick Wise's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -12.44% per trade.
---